New Data from Biogen's Investigational Antisense Oligonucleo

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Boston , Massachusetts , America , Priya Singhal , Jack Cox , Chuck Triano , Asia Pacific , Youtube , Brightfocus Foundation , Linkedin , Alzheimer Association , Exchange Commission , Head Of Development At Biogen , International Conference On Alzheimer , Biogen Inc , Nasdaq , Facebook , Investigational Antisense Oligonucleotide , Targeting Tau Shows Promise , Potential New Generation , Early Alzheimer , Clinical Dementia Rating Sum , Mini Mental State Exam , Functional Activities Questionnaire , International Conference , North America , Safe Harbor , Tau Protein , Accessed September , From Discovery , Tau Topic , Accessed October ,